Roche to invest $50B in US pharmaceuticals - Breaking The News

Roche to invest $50B in US pharmaceuticals

22 April

1 min read

EPA-EFE/ALEXANDRA WEY

F. Hoffmann-La Roche AG announced on Tuesday that it will invest $50 billion in the United States over the next five years.

Roche hopes to strengthen already established manufacturing and open new facilities, starting with Indiana, Pennsylvania, Massachusetts, and California. As part of the investment, the number of employees will increase by more than 12,000.

"Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today's announced investments underscore our long-standing commitment to research, development and manufacturing in the US," said Roche Group CEO Thomas Schinecker.

roche

Related Stocks

Roche Holding Gen.r.

Roche's Q1 sales up 6% to 15.4 billion Swiss francs

24 April

F. Hoffmann-La Roche AG said on Thursday its sales in the first quarter of fiscal 2025 reached 15.4 billion Swiss francs, climbing 7% in Swiss francs and 6% at constant exchange rates (CER) from the same period a year earlier. Sales in the pharmaceuticals division grew 8% at CER to 11.95 billion Swiss francs, while diagnostics division sales amounted to 3.49 Swiss francs, virtually unchanged from the same timeframe in 2024."We had a good start to the year with...

Pharma stocks drop in Europe amid Trump tariff plans

9 April

Stocks of major European pharmaceutical companies, including French Sanofi, British GSK and AstraZeneca, as well as Swiss Roche and Novartis, saw a decline on Wednesday following US President Donald Trump's announcement of a "major tariff" on pharmaceuticals. Trump revealed that Washington would soon impose the tariff, prompting concerns among investors about the potential impact on the global market.At 10:18 am CET, Novartis AG nosedived...

Roche's 2024 sales up 7% to 60.5B Swiss francs

30 January

F. Hoffmann-La Roche AG said on Thursday its annual sales in 2024 reached 60.5 billion Swiss francs, climbing 3% in Swiss francs and 7% at constant exchange rates (CER) from the same period a year earlier. Sales in the pharmaceuticals division grew 8% at CER to 46.2 billion Swiss francs, while diagnostics division sales rose 4% at CER year on year to 14.3 billion Swiss francs.In the year, net income dropped 19% at CER to 9.2 billion Swiss francs...

Roche to buy Poseida Therapeutics for $1.5B

26 November

F. Hoffmann-La Roche AG announced on Tuesday that it is acquiring Poseida Therapeutics Inc. for around $9 per share in cash or $1 billion in total. Shareholders will also receive a non-tradeable contingent value right (CVR) of up to $4 per share, bringing the deal value up to $1.5 billion. The transaction is expected to close in the first quarter of 2025.The two companies have collaborated since 2022 on developing off-the-shelf CAR-T cell therapies for patients...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.